Determination That THORAZINE (Chlorpromazine Hydrochloride) Tablets and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Federal Register, Volume 81 Issue 13 (Thursday, January 21, 2016)
Federal Register Volume 81, Number 13 (Thursday, January 21, 2016)
Notices
Pages 3430-3431
From the Federal Register Online via the Government Publishing Office www.gpo.gov
FR Doc No: 2016-01097
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Docket No. FDA-2016-N-0119
Determination That THORAZINE (Chlorpromazine Hydrochloride) Tablets and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.
FOR FURTHER INFORMATION CONTACT: Stacy Kane, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6207, Silver Spring, MD 20993-0002, 301-796-8363, Stacy.Kane@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products approved under an ANDA procedure. ANDA applicants must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength and dosage form as the ``listed drug,'' which is a version of the drug that was previously approved. ANDA applicants do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA).
The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the ``Approved Drug Products With Therapeutic Equivalence Evaluations,'' which is generally known as the ``Orange Book''. Under FDA regulations, a drug is removed from the list if the Agency withdraws or suspends approval of the drug's NDA or ANDA for reasons of safety or effectiveness, or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162).
Under Sec. 314.161(a) (21 CFR 314.161(a)), the Agency must determine whether a listed drug was withdrawn from sale for reasons of safety or effectiveness: (1) Before an ANDA that refers to that listed drug may be approved, (2) whenever a listed drug is voluntarily withdrawn from sale and ANDAs that refer to the listed drug have been approved, and (3) when a person petitions for such a determination under 21 CFR 10.25(a) and 10.30. Section 314.161(d) provides that if FDA determines that a listed drug was withdrawn from sale for safety or effectiveness reasons, the Agency will initiate proceedings that could result in the withdrawal of approval of the ANDAs that refer to the listed drug.
FDA has become aware that the drug products listed in the table in this document are no longer being marketed.
------------------------------------------------------------------------
Application No. Drug Applicant
------------------------------------------------------------------------
NDA 009149........... THORAZINE (chlorpromazine GlaxoSmithKline.
hydrochloride (HCl)) Tablet;
Oral, 10 milligrams (mg); 25
mg; 50 mg; 100 mg; 200 mg.
NDA 016793........... CYTARABINE (cytarabine) Teva
Injectable; Injection, 100 mg/ Pharmaceuticals
vial; 500 mg/vial; 1 gram (g)/ USA, Inc.
vial; 2 g/vial.
NDA 018343........... CAPOTEN (captopril) Tablet; Par
Oral, 37.5 mg; 75 mg; 150 mg. Pharmaceutical,
Inc.
NDA 020845........... INOMAX (nitric oxide) Gas; Ino
Inhalation, 100 parts per Therapeutics,
million. Inc.
NDA 021178........... GLUCOVANCE (glyburide; Bristol-Myers
metformin HCl) Tablet; Oral, Squibb
1.25 mg; 250 mg.
NDA 050443........... BLENOXANE (bleomycin sulfate) Bristol-Myers
Injectable; Injection, EQ 15 Squibb
units base/vial; EQ 30 units
base/vial.
NDA 050526........... STATICIN (erythromycin) Westwood-Squibb
Solution; Topical, 1.5%. Pharmaceuticals
, Inc.
NDA 050675........... VANTIN (cefpodoxime proxetil) Pharmacia &
For Suspension; Oral, EQ 50 mg Upjohn Co.
base/5 mL; EQ 100 mg base/5 mL.
NDA 203595........... SUCLEAR (magnesium sulfate, Braintree
polyethylene glycol 3350, Laboratories,
potassium chloride, potassium Inc.
sulfate, sodium bicarbonate,
sodium chloride, sodium
sulfate) Solution; Oral, 1.6
g, 210 g, 0.74 g, 3.13 g, 2.86
g, 5.6 g, 17.5 g.
ANDA 061827.......... CLEOCIN (clindamycin palmitate Pharmacia &
HCl) For Solution; Oral, EQ 75 Upjohn Co.
mg base/5 mL.
Page 3431
ANDA 062436.......... T-STAT (erythromycin) Solution; Westwood-Squibb
Topical, 2%. Pharmaceuticals
, Inc.
ANDA 080439.......... CHLORPROMAZINE HCl Sandoz Inc.
(chlorpromazine HCl) Tablet;
Oral, 10 mg; 25 mg; 50 mg; 100
mg; 200 mg.
------------------------------------------------------------------------
FDA has reviewed its records and, under Sec. 314.161, has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. Accordingly, the Agency will continue to list the drug products listed in this document in the ``Discontinued Drug Product List'' section of the Orange Book. The ``Discontinued Drug Product List'' identifies, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness.
Approved ANDAs that refer to the NDAs and ANDAs listed in this document are unaffected by the discontinued marketing of the products subject to those NDAs and ANDAs. Additional ANDAs that refer to these products may also be approved by the Agency if they comply with relevant legal and regulatory requirements. If FDA determines that labeling for these drug products should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling.
Dated: January 14, 2016.
Leslie Kux,
Associate Commissioner for Policy.
FR Doc. 2016-01097 Filed 1-20-16; 8:45 am
BILLING CODE 4164-01-P
